quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·140d
PRRelease
Biomea Fusion Inc. logo

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

BMEA· Biomea Fusion Inc.
Health Care
Original source

Companies

  • BMEA
    Biomea Fusion Inc.
    Health Care

Recent analyst ratings

  • Jan 13UpdateRodman & Renshaw$8.00
  • Aug 28UpdateJefferies$5.00
  • Jun 3UpdatePiper Sandler$7.00
  • Oct 9UpdateEdward Jones$128.00
  • Sep 27UpdateRodman & Renshaw$18.00
  • Sep 27UpdateTruist$54.00

Related

  • INSIDER20d
    SEC Form 4 filed by Erdtmann Rainer M
  • INSIDER20d
    SEC Form 4 filed by Hitchcock Michael J.M.
  • PR24d
    Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
  • SEC30d
    SEC Form 10-K filed by Biomea Fusion Inc.
  • SEC30d
    Biomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR30d
    Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
  • PR41d
    Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
  • SEC58d
    Biomea Fusion Inc. filed SEC Form 8-K: Regulation FD Disclosure
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022